MannKind Corporation's diversified pipeline and royalty streams support $8.50 price target, implying 134% upside

BioEquity Watch··Read original
2▲2 ▼0Impact / 5
Summary · why it matters

A bullish thesis on MannKind Corporation highlights the company's transformation into a diversified healthcare business with three revenue streams: Afrezza inhaled insulin, Furoscix for heart failure, and high-margin royalties from Tyvaso DPI through its partnership with United Therapeutics. Management has shifted focus toward pulmonary and cardiovascular diseases and broadened the revenue base with the acquisition of scPharmaceuticals. Financially, MannKind generated $349 million in 2025 revenue, grew sales by 22%, eliminated its remaining debt, and held $134 million in cash as of March 2026. A risk-adjusted sum-of-the-parts valuation derives a target price of $8.50 per share, implying approximately 134% upside from the June 24th price of $3.84, with a blue-sky range of $10 to $12 per share if regulatory and clinical milestones are met.

Impact on assets 4

Biotech & Genomic Medicine▲ · 3 stocks
MannKind Corp
MNKD
▲ PositiveCapitalrelevance

Article is a bullish thesis on MannKind, highlighting revenue growth, debt elimination, and $8.50 price target with 134% upside.

United Therapeutics Corporation
UTHR
▲ PositiveDemandrelevance

MannKind's high-margin royalties from Tyvaso DPI through partnership with United Therapeutics are mentioned as a revenue stream, implying positive demand for United's product.

Digital Finance & Tokenization▲ · 1 stocks
© 2026 MarketIVNews